Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: a case report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, Ye Won | - |
dc.contributor.author | Bae, Hyo Sook | - |
dc.contributor.author | Han, Song I. | - |
dc.contributor.author | Song, Jae Yoon | - |
dc.contributor.author | Kim, In Sun | - |
dc.contributor.author | Kang, Jae Seong | - |
dc.date.accessioned | 2021-09-07T22:33:59Z | - |
dc.date.available | 2021-09-07T22:33:59Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2010-12 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/115241 | - |
dc.description.abstract | Toremifene is an anti-estrogen which has been shown to be effective in the treatment of breast cancer, and is thought to be a less uterotrophic agent than tamoxifen. The risk assessment concerning endometrial cancer has been inconclusive because of its rare use up to the mid-1990s. We report a case of an adenosarcoma, which is a very rare type of uterine malignancy, after toremifene treatment for 5 years in a breast cancer patient. After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma. After an additional 4 years of toremifene treatment, the endometrial polypoid lesion was transformed into a Mullerian adenosarcoma. Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY | - |
dc.subject | TAMOXIFEN | - |
dc.subject | THERAPY | - |
dc.subject | EFFICACY | - |
dc.subject | SAFETY | - |
dc.subject | UTERUS | - |
dc.subject | TRIAL | - |
dc.title | Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: a case report | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Jae Yoon | - |
dc.contributor.affiliatedAuthor | Kim, In Sun | - |
dc.contributor.affiliatedAuthor | Kang, Jae Seong | - |
dc.identifier.doi | 10.3802/jgo.2010.21.4.269 | - |
dc.identifier.scopusid | 2-s2.0-79952391751 | - |
dc.identifier.wosid | 000285808900011 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, v.21, no.4, pp.269 - 272 | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.citation.title | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.citation.volume | 21 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 269 | - |
dc.citation.endPage | 272 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001511534 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
dc.subject.keywordPlus | TAMOXIFEN | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | UTERUS | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Toremifene | - |
dc.subject.keywordAuthor | Tamoxifen | - |
dc.subject.keywordAuthor | Mullerian adenosarcoma | - |
dc.subject.keywordAuthor | Mullerian adenofibroma | - |
dc.subject.keywordAuthor | Breast cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.